Axsome Therapeutics Reports Issuance of U.S. Patent Covering AXS-02 for the Treatment of Bone Marrow Lesions of the Knee

Axsome Therapeutics, Inc. (NASDAQ:AXSM) announced that the US Patent and Trademark Office has issued a patent (U.S. Patent No. 9,211,257), which provides coverage for AXS-02, one of Axsome’s late-stage product candidates.
According to the company press release:

The patented claims cover the use of zoledronic acid, the active moiety in AXS-02, for the treatment of bone marrow lesions (BMLs) of the knee. AXS-02 is in development for the pain of knee osteoarthritis associated with BMLs. The term of the issued patent extends into 2033.

Click here to view the full press release.